Valink Therapeutics GTM brain

Valink Therapeutics discovers bispecific antibody-drug conjugates for solid tumors and seeks pharmaceutical discovery collaborators.

category

Bispecific antibody-drug conjugate discovery

market profile

  • text: Solid tumors and drug resistance motivate more selective antibody-drug conjugate designs; Valink's assets are in discovery and preclinical development.
  • text: The company seeks discovery-engine collaborations and asset discussions with biotechnology and pharmaceutical partners.

personas

  • title: Oncology business development and licensing leader
    pains:
    • Needs differentiated early-stage assets for solid tumor pipelines.
    • Must evaluate preclinical evidence, intellectual property and development risk before committing capital.
  • title: Biopharma head of antibody discovery
    pains:
    • Identifying productive dual-target combinations and optimizing complex molecules requires substantial screening capacity.
    • Needs compelling evidence of tumor selectivity and payload delivery.
  • title: Translational oncology R&D leader
    pains:
    • Existing therapies can face resistance or damage healthy tissue.
    • Needs biomarker strategies and preclinical validation before clinical investment.

icp

  • text: Pharmaceutical and biotechnology companies developing oncology therapeutics or seeking externally sourced preclinical ADC assets.
  • text: Antibody discovery and platform organizations with complementary technologies are plausible collaboration partners, as illustrated by Nona Biosciences.

message pillars

  • text: Aim to attack tumors while sparing healthy tissue.
  • text: Improve the antibody component of ADC design.
  • text: Use a discovery engine to search for new bispecific ADCs.
  • text: Explore interactions beyond simple binary target gating.

objections

  • objection: Is selectivity and efficacy proven in patients?
    response: The public pipeline shows discovery and preclinical work; request supporting data and distinguish hypotheses from clinical outcomes.
  • objection: How does the platform differ from other bispecific ADC approaches?
    response: Discuss V-Gate target response and LiliumX screening, and request comparative data for the relevant asset.
  • objection: Can a partnership protect our target and IP?
    response: Evaluate target rights, exclusivity, data access and development obligations in diligence and a negotiated agreement.

competitors

  • name: DualityBio
    website: https://en.dualitybiologics.com/global/index.html
    why: Develops and licenses ADCs including an EGFR/HER3 bispecific ADC.
  • name: Biocytogen
    website: https://biocytogen.com/news/biocytogen-and-whitehawk-therapeutics-enter-global-collaboration-for-bispecific-antibody-adc-development-us
    why: Its antibody discovery platform supports bispecific ADC collaborations.

influencers

  • name: Irsyad Khairil
    url: https://www.linkedin.com/posts/valinktx_aacr26-activity-7450832046475759616-pBqs
    why: Co-founder and CTO representing the company at oncology research events.

keywords

  • bispecific antibody drug conjugate
  • bispecific ADC discovery platform
  • tumor selective ADC
  • solid tumor ADC pipeline
  • antibody target combinations
  • oncology licensing preclinical ADC

voice

  • Science-led and ambitious
  • Patient-centered
  • Technical but accessible

signals

  • text: A pharma company is expanding oncology ADC partnerships or licensing preclinical assets.
  • text: A discovery organization seeks complementary bispecific antibody or payload technologies.

stack

  • LiliumX discovery platform
  • high-throughput functional screening
  • AI

pricing

model: unknown

motion

sales_led

channels

  • scientific conferences
  • LinkedIn
  • business development
  • press
  • research partnerships

confidence

medium

Founders

  • name: Arne Scheu
    title: Founder
    role: Founder
    bio: Rhodes Scholar & DPhil Biochemistry from the University of Oxford
  • name: Irsyad Khairil
    title: Founder
    role: Founder
    bio: Pharma analyst with a background in protein engineering DPhil in Biochemistry from the University of Oxford

Back to YC companies